Back to results
US 2019/0023661 A1Published application
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis pain.
Claims22
A method of safely and effectively delivering zoledronic acid to the blood of a human being through repeated oral administration comprising:
- orally administering a pharmaceutical composition comprising zoledronic acid in a salt form to the human being at least once a month and no more frequently than once a day, wherein the pharmaceutical composition is administered to the human being in a fasted state;
- wherein the pharmaceutical composition is free of bioavailability enhancing agents;
- wherein the pharmaceutical composition is in a form of a pill, a tablet, or a capsule, and the pharmaceutical composition contains about 0.15 millimoles to about 2.2 millimoles of the zoledronic acid in the salt form;
- and
- wherein orally administering the pharmaceutical composition to the human being results in an oral bioavailability of zoledronic acid that is 1.1% to about 3%.
2 more elements
A method of treating pain comprising:
- orally administering a pharmaceutical composition comprising zoledronic acid, in an acid form or a salt form, to a human being in need thereof at least once a month and no more frequently than once a day, wherein the pharmaceutical composition is administered to the human being in a fasted state;
- wherein the human being is not suffering from cancer;
- wherein the pharmaceutical composition is free of bioavailability enhancing agents;
- wherein the pharmaceutical composition is in a form of a pill, a tablet, or a capsule, and the pharmaceutical composition contains about 0.15 millimoles to about 2.2 millimoles of the zoledronic acid;
- and
- wherein orally administering the pharmaceutical composition to the human being results in an oral bioavailability of zoledronic acid that is 1.1% to about 3%.
3 more elements
Dependencies are inferred from the claim text.